| Early mortality in atezolizumab/bevacizumab for unresectable hepatocellular carcinoma: European, real-world study A Philipp, I Piseddu, LS Jochheim, K Boettcher, B Scheiner, F Sinner, ... Zeitschrift für Gastroenterologie 62 (05), K3, 2024 | | 2024 |
| Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multi-center real world study with focus on bleeding and thromboembolic events NB Khaled, M Möller, LS Jochheim, C Leyh, U Ehmer, K Böttcher, ... JHEP Reports, 101065, 2024 | 1 | 2024 |
| T. 07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner, A D'Alessio, GF Manfredi, ... Digestive and Liver Disease 56, S255, 2024 | | 2024 |
| Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease N Dominik, B Scheiner, A Zanetto, L Balcar, G Semmler, E Campello, ... Alimentary Pharmacology & Therapeutics, 2024 | | 2024 |
| Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner, A D’Alessio, GF Manfredi, ... Journal of Hepatology 80 (3), 431-442, 2024 | 6 | 2024 |
| Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner, A d'Alessio, GF Manfredi, ... Digestive and Liver Disease 56, S76-S78, 2024 | | 2024 |
| Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma GF Manfredi, CAM Fulgenzi, A D'Alessio, C Celsa, B Stefanini, J Cheon, ... Digestive and Liver Disease 56, S8-S9, 2024 | | 2024 |
| Controversies in upper GI oncology: first-line systemic treatment in MASLD-associated HCC J Dekervel, A Casadei-Gardini, M Pinter ESMO open 9 (2), 2024 | | 2024 |
| A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma L Balcar, B Scheiner, CAM Fulgenzi, A D’Alessio, K Pomej, MB Roig, ... JHEP reports 6 (2), 100982, 2024 | 1 | 2024 |
| Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia. CAM Fulgenzi, T El Zarif, A Nassar, E Adib, J Bellmunt, TU Marron, ... Journal of Clinical Oncology 42 (3_suppl), 442-442, 2024 | | 2024 |
| Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child–Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the … YJ Kim, P Merle, RS Finn, M Kudo, HJ Klümpen, HY Lim, M Pinter, ... Journal of Clinical Oncology 42 (3_suppl), 452-452, 2024 | | 2024 |
| Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real … C Celsa, N Nishida, A Arvind, SV Ulahannan, M Li, B Scheiner, ... Journal of Clinical Oncology 42 (3_suppl), 501-501, 2024 | | 2024 |
| Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion L Balcar, A Mrekva, B Scheiner, K Pomej, T Meischl, M Mandorfer, ... Cancer Imaging 24 (1), 9, 2024 | 1 | 2024 |
| Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient M Jachs, L Hartl, B Simbrunner, G Semmler, L Balcar, BS Hofer, ... Journal of Hepatology, 2024 | 3 | 2024 |
| Prediction of response to atezolizumab/bevacizumab in advanced hepatocellular carcinoma through radiomic features in pretreatment MRI I Rodriguez, M Venerito, D Tamandl, M Pinter, M Ebert, DH Chang, M Dill, ... Zeitschrift für Gastroenterologie 62 (01), P4. 31, 2024 | | 2024 |
| Platelet adhesion assessed by PFA-100 is not linked to progression of ACLD L Balcar, B Simbrunner, R Paternostro, M Jachs, L Hartl, G Semmler, ... JHEP Reports 6 (1), 100934, 2024 | 2 | 2024 |
| Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma GF Manfredi, C Celsa, C John, C Jones, N Acuti, B Scheiner, ... Journal of Hepatocellular Carcinoma, 1955-1971, 2023 | 1 | 2023 |
| Mast cell activation index and neoantigen load in a pan-analysis of cancers N Rohr-Udilova, M Pinter, M Trauner, E Jensen-Jarolim, R Bianchini ALLERGY 78, 232-232, 2023 | | 2023 |
| 111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours C Celsa, G Cabibbo, TU Marron, A Saeed, M Pinter, YH Huang, A Pillai, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study Q Zeng, C Klein, S Caruso, P Maille, DS Allende, B Mínguez, M Iavarone, ... The Lancet Oncology 24 (12), 1411-1422, 2023 | 16 | 2023 |
